Position of the Transparency Council – Zynlonta (lonkastuximab thesirine)

At its meeting on 1 July 2024, the Transparency Council adopted position No. 61/2024 on the evaluation of the drug Zynlonta (lonkastuximab thesirine) within the framework of the drug program “Treatment of patients with B-cell lymphoma (ICD-10: C82, C83, C85)”

Publication of the position >>